|Mr. Eyal Barad||Co-Founder, CEO & Director||206.95k||N/A||1965|
|Dr. Eyal Ballan Ph.D.||Co-founder, CTO & Director||255.03k||N/A||1976|
|Mr. Uri Ben-Or CPA, M.B.A., CPA, MBA||CFO & Principal Accounting Officer||N/A||N/A||1970|
|Mr. David E. Price||Sec. & Corp. Counsel||N/A||N/A||1965|
|Mr. Yasha Borstein||Chief Data Officer||N/A||N/A||1963|
Cannabics Pharmaceuticals Inc., an early stage biotechnology company, engages in the development and licensing of cannabinoid-based treatments and therapies. The company focuses on developing and marketing therapies and biotechnological tools for the relief from various ailments that respond to active ingredients sourced from the cannabis plant. It offers Cannabics SR, a medical cannabis capsules to treat cancer related cachexia/anorexia syndrome in advanced cancer patients. The company also focuses on the commercialization of a diagnostic test based on liquid biopsies of patients suffering from epithelial cancers; and development of diagnostics that monitor cancer progression and cannabinoid cancer sensitivity tests for the treatment of cancer with cannabinoid medicine. Cannabics Pharmaceuticals Inc. has a collaboration with SIMFO GmbH for circulating tumor cell drug sensitivity tests. The company was formerly known as American Mining Corporation and changed its name to Cannabics Pharmaceuticals Inc. in May 2014. Cannabics Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. Cannabics Pharmaceuticals Inc. is a subsidiary of Cannabics Inc.
Cannabics Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.